As a c-MET-targeting peptide, c-MET-binding peptide (cMBP) has been developed for tumor imaging and gene delivery.15–17 Therefore, instead of intravenous delivery of NIR fluorescence dye, we propose that topically applied, NIR fluorescently labeled, simply synthesized homing-peptide–based, oral SCC-targeting contrast agent, c-MET-binding peptide-indocyanine green (cMBP-ICG), can be preferable for superficial, invasive, and heterogenous tumors such as oral SCC. The gene discussed is MET; the disease is neoplasm.